Alpha or beta emitters attached to fragments in radioimmunotherapy
AssigneeCenter for Molecular Medicine and Immunology
InventorsDavid M. Goldenberg, Thomas M. Behr
Life of this patent
Estimating the term…
Abstract
The present invention relates to radioimmunoconjugates useful in targeted radioimmunotherapy and methods of treating a patient using radioimmunoconjugates. The radioimmunoconjugates of the present invention comprise an alpha- or beta-emitting radioisotope and a binding site linked to or on an antigen-binding fragment of an antibody which specifically binds to a tumor-associated antigen. The methods of treating a patient can include administering one or more clearing agents to the patient in conjunction with the radioimmunoconjugate of the present invention, as well as subsequently grafting bone-marrow or autologous stem-cells to the patient.
Claims14
A kit for radioimmunotherapy, comprising:
- a molecule with a radioisotope binding site linked to or on an antigen-binding fragment of an antibody that specifically binds to a tumor-associated antigen;
- and at least two clearing agents,
- wherein said clearing agents are at least (A) a metal-chelating clearing agent, and (B) an amino acid bearing an amino basic side group or a peptide bearing an amino basic side group.
A kit for radioimmunotherapy, comprising:
- a molecule with a radioisotope binding site linked to or on an antigen-binding fragment of an antibody that specifically binds to a tumor-associated antigen;
- and at least two clearing agents,
- wherein said clearing agents are at least (A) an antibody directed to an epitope on the molecule, wherein the antibody acts as a clearing agent, and (B) an amino acid bearing an amino basic side group or a peptide bearing an amino basic side group.
Dependencies are inferred from the claim text.